Screening of nonalcoholic fatty liver disease in patients with coronary heart disease by transient elastography: proceed with caution
We read the article by Mikolasevic et al. with great interest. Mikolasevic et al. using transient elastography (TE) as a screening tool to detect nonalcoholic fatty liver disease (NAFLD) in patients with coronary heart disease was a novel approach. We have previously reported, for the first time in the world, that TE can be used to measure the severity of fibrosis in patients with NAFLD, and TE has been validated by several meta-analyses today. TE received the long-awaited approval from US Food and Drug Administration on April 5, 2013, and it is expected that the use of TE will subsequently increase in not only Europe but also the USA.